Comparison of pyridostigmine and bisacodyl in the treatment of refractory chronic constipation

Caspian Journal of Internal Medicine

Volumn 7, Issue 1, 2016, Pages 19-24

  Soufi Afshar, Iman ^a   Moghadamnia, Aliakbar ^a   Bijan, Ali ^a   Kazemi, Sohrab ^a   Shokri Shirvani, Javad ^a  

^a BABOL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anti cholinesterase; Chronic constipation; Constipation; Pyridostigmine

Indexed keywords

BISACODYL; PYRIDOSTIGMINE;

ADULT; ARTICLE; BRISTOL STOOL FORM SCALE; CHRONIC CONSTIPATION; CLINICAL FEATURE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DEFECATION; DEFECATION MEASUREMENT; DOUBLE BLIND PROCEDURE; FECES COMPOSITION; FEMALE; GASTROINTESTINAL MOTILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; QUESTIONNAIRE; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

EID: 84955514358     PISSN: 20086164     EISSN: 20086172     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993; 38: 1569-80.
2. Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroen-terol 2004; 99: 750-9.
3. Singh G, Lingala V, Wang H, et al. Use of health care resources and cost of care for adults with constipation. Clin Gastroenterol Hepatol 2007; 5: 1053-8.
4. Lembo A, Camilleri M. Chronic constipation. N Engl J Med 2003; 349: 1360-8.
5. O'Keefe EA, Talley NJ, Zinsmeister AR, Jacobsen SJ. Bowel disorders impair functional status and quality of life in the elderly: a population-based study. J Gerontol A Biol Sci Med Sci 1995; 50: 184-9.
6. Chang L. Review article: epidemiology and quality of life in functional gastrointestinal disorders. Aliment Pharma-col Ther 2004; 20: 31-9.
7. Bharucha AE, Low P, Camilleri M, et al. A randomised controlled study of the effect of cholinesterase inhibition on colon function in patients with diabetes mellitus and constipation. Gut 2013; 62: 708-15.
8. Chang L. Review article: epidemiology and quality of life in functional gastrointestinal disorders. Aliment Pharma-col Ther 2004; 20: 31-9.
9. Preston DM, Lennard-Jones JE. Severe chronic constipation of young women: idiopathic slow transit constipation. Gut 1986; 27: 41-8.
10. Mertz H, Naliboff B, Mayer EA. Symptoms and physiology in severe chronic constipation. Am J Gastroenterol 1999; 94: 131.
11. Cuppoletti J, Malinowska DH, Tewari KP, et al. SP1-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol 2004; 287: C1173-83.
12. .Burleigh DE. Evidence for a functional cholinergic deficit in human colonic tissue resected for constipation. J Pharm Pharmacol 1988; 40: 55-7.
13. Law NM, Bharucha AE, Undale AS, Zinsmeister AR. Cholinergic stimulation enhances colonic motor activity, transit, and sensation in humans. Am J Physiol Gastrointest Liver Physiol 2001; 281: 1228-37.
14. Polinsky RJ, Kopin IJ, Ebert MH, Weise V. Pharmacologic distinction of different orthostatic hypotension syndromes. Neurology J 1981; 31: 1-7.
15. Wattchow DA, Brookes SJH, Murphy EM, et al. Regional variation in the neurochemical coding of the myenteric plexus of the human colon and changes in patients with slow transit constipation. Neurogastroenterol Motil 2008; 20: 1298-305.
16. Malekzadeh F, Ansari R, Malekzadeh R. Do you mean: Approach to chronic constipation. Govaresh 2014; 19: 7-13.
17. Sadjadpour K. Pyridostigmine bromide and constipation in Parkinson's disease. JAMA 1983; 249: 1148-60.
18. Xing JH, Soffer EE. Adverse effects of laxatives. Dis Colon Rectum 2001; 44: 1201-9.
19. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997; 32: 920-4.
20. Camilleri M, McKinzie S, Fox J, et al. Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2004; 2: 895-904.
21. Bharucha AE, Low PA, Camilleri M, et al. Pilot study of pyridostigmine in constipated patients with autonomic neuropathy. Clin Auton Res 2008; 18: 194-202.
22. Prather CM, Camilleri M, Zinsmeister AR, et al. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000; 118: 463-468.
23. Whitehead WE, Palsson OS, Gangarosa L, et al. Lubiprostone does not influence visceral pain thresholds in patients with irritable bowel syndrome. Neurogastroenterol Motil 2011; 23: 944.
24. Andresen V, Camilleri M, Busciglio IA, et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 2007; 133: 761-8.
25. Bharucha AE, Low P, Camilleri M, et al. A randomized controlled study of the effect of cholinesterase inhibition on colon function in patients with diabetes mellitus and constipation. Gut 2013; 62: 708-15.
26. Nagahama K, Matsunaga Y, Kawachi M, et al. Acotiamide, a new orally active acetylcholinesterase inhibitor, stimulated gastrointestinal motor activity in conscious dogs. Neurogastroenterol Motil 2012; 24: 566-74.
27. O'Dea CJ, Brookes JH, Wattchow DA. The efficacy of treatment of patients with severe constipation or recurrent pseudo-obstruction with pyridostigmine. Colorectal Dis 2010; 12: 540-8.
28. Shokry-Shirvani J, Taheri H, Shad E, Bijani A, Kashifard M. Efficacy of domperidone and pyridostigmine in the treatment of patients with functional dyspepsia: A Randomized clinical trial. Govaresh J 2012; 17; 7-12.
29. Golomb BA. Acetylcholinesterase inhibitors and Gulf war illnesses. Proc Natl Acad Sci U S A. 2008; 105:4295-4300.
30. Breyer-Pfaff U, Schmezer A, Maier U, Brinkmann A, Schumm F. Neuromuscular function and plasma drug levels in pyridostigmine treatment of myasthenia gravis. J Neurol Neurosurg Psychiatry 1990; 53: 502-6.